Equities analysts forecast that BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) will report $5.77 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for BioCryst Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $3.18 million and the highest estimate coming in at $9.20 million. BioCryst Pharmaceuticals reported sales of $8.98 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 35.7%. The firm is expected to report its next earnings results on Monday, February 26th.

On average, analysts expect that BioCryst Pharmaceuticals will report full year sales of $5.77 million for the current year, with estimates ranging from $18.82 million to $30.50 million. For the next financial year, analysts expect that the company will post sales of $26.45 million per share, with estimates ranging from $16.75 million to $35.19 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow BioCryst Pharmaceuticals.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.18). BioCryst Pharmaceuticals had a negative net margin of 167.58% and a negative return on equity of 123.16%. The firm had revenue of $8.76 million during the quarter, compared to analysts’ expectations of $5.05 million. During the same period last year, the business earned ($0.16) earnings per share. BioCryst Pharmaceuticals’s revenue was up 12.9% compared to the same quarter last year.

BCRX has been the subject of several recent analyst reports. Piper Jaffray Companies restated an “overweight” rating and set a $15.00 price objective (up from $13.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday, September 5th. Noble Financial reiterated a “buy” rating on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 8th. ValuEngine upgraded shares of BioCryst Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, August 28th. Zacks Investment Research cut shares of BioCryst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, August 10th. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a research report on Wednesday, September 6th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and seven have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $9.13.

In related news, CMO William P. Sheridan sold 64,310 shares of BioCryst Pharmaceuticals stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $4.72, for a total value of $303,543.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Fred E. Cohen sold 54,250 shares of BioCryst Pharmaceuticals stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $5.42, for a total transaction of $294,035.00. Following the completion of the transaction, the director now owns 173,660 shares of the company’s stock, valued at approximately $941,237.20. The disclosure for this sale can be found here. Insiders own 5.80% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. UBS Asset Management Americas Inc. acquired a new position in shares of BioCryst Pharmaceuticals in the first quarter valued at approximately $392,000. Schwab Charles Investment Management Inc. grew its holdings in shares of BioCryst Pharmaceuticals by 23.2% in the first quarter. Schwab Charles Investment Management Inc. now owns 333,373 shares of the biotechnology company’s stock valued at $2,801,000 after purchasing an additional 62,792 shares in the last quarter. OxFORD Asset Management LLP acquired a new position in shares of BioCryst Pharmaceuticals in the second quarter valued at approximately $660,000. RA Capital Management LLC grew its holdings in shares of BioCryst Pharmaceuticals by 47.9% in the second quarter. RA Capital Management LLC now owns 5,162,242 shares of the biotechnology company’s stock valued at $28,702,000 after purchasing an additional 1,672,447 shares in the last quarter. Finally, Teachers Advisors LLC grew its holdings in shares of BioCryst Pharmaceuticals by 55.9% in the second quarter. Teachers Advisors LLC now owns 196,385 shares of the biotechnology company’s stock valued at $1,092,000 after purchasing an additional 70,438 shares in the last quarter. Hedge funds and other institutional investors own 71.30% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “$5.77 Million in Sales Expected for BioCryst Pharmaceuticals, Inc. (BCRX) This Quarter” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/11/18/5-77-million-in-sales-expected-for-biocryst-pharmaceuticals-inc-bcrx-this-quarter.html.

Shares of BioCryst Pharmaceuticals (NASDAQ BCRX) opened at $4.52 on Friday. BioCryst Pharmaceuticals has a 12-month low of $3.95 and a 12-month high of $9.25. The company has a quick ratio of 2.53, a current ratio of 2.53 and a debt-to-equity ratio of 0.21.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Get a free copy of the Zacks research report on BioCryst Pharmaceuticals (BCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Stock Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.